Phase IIb data show that BG-12 significantly reduced brain lesions in patients with relapsing-remitting multiple sclerosis, with a 53% reduction in T1-hypointense lesions. The treatment also demonstrated favorable safety and potential neuroprotective benefits.
Baminercept alfa, a dual-mechanism inhibitor of the LT-β and LIGHT pathway, has shown improved efficacy in patients with rheumatoid arthritis, including reduced swollen joint count and tender joint count. The Phase IIa trial results suggest that baminercept alfa is well-tolerated and may be effective in treating RA
In a phase II clinical trial, 70% of patients with follicular lymphoma responded to treatment with galiximab and rituximab. The combination regimen achieved complete responses in 44% and partial responses in 26%. Further study is warranted to assess the efficacy and time-to-progression endpoint.